Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mayne Glucagon · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Glucagen |
| 2 | EXPERIMENTAL | Mayne Glucagon |
| Name | Type | Description |
|---|---|---|
| Glucagen | DRUG | 0.2 mg or 1 mg Glucagen single injection |
| Mayne Glucagon | DRUG | 0.2 mg or 1 mg Mayne Glucagon |
Inclusion Criteria: * Healthy Male or female aged 18-50 years inclusive * Body weight between 50 - 100 kg and body mass index (BMI) between 18 and 30 kg/m2 or, if outside the range, considered not clinically significant by the investigator * Non-smokers or ex-smokers who have not smoked with in the...
Mayne Glucagon is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for hypoglycemia, a metabolic condition marked by low blood glucose. It is in Phase 1 clinical development. The program has studied a glucagon formulation for injection in healthy adult volunteers.
Mayne Glucagon is being developed for hypoglycemia, a metabolic condition involving abnormally low blood glucose. The only clinical trial of the asset enrolled healthy adult volunteers rather than patients with hypoglycemia, and it evaluated the pharmacokinetics and pharmacodynamics of the injection.
Mayne Glucagon is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program for the asset in hypoglycemia.
Mayne Glucagon is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials of the asset are currently active.
Mayne Glucagon has been studied in one completed Phase 1 trial, NCT00745186, titled Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen (Novo Nordisk) in Healthy Volunteers. The trial enrolled 28 healthy adult participants in the United Kingdom and used an active-controlled, randomized design.
NCT00745186 compared the pharmacokinetics and pharmacodynamics of Mayne Glucagon for injection with Glucagen, a Novo Nordisk glucagon product, in healthy volunteers. The Phase 1 study was randomized and active-controlled, enrolled 28 participants aged 18 years and older in the United Kingdom, and has been completed.